drugset / Trial / NCT05377112
Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome
RandomizedParallel-groupDouble-blindTreatment
Summary
Study SYNB8802-CP-002 is designed to assess safety, tolerability, and oxalate lowering, in subjects with a history of gastric bypass surgery or short-bowel syndrome. In addition, this study will explore other PD effects relative to baseline as well as predictors of efficacy and tolerability.
Timeline
- Start
- 2022-03-29
- Primary completion
- 2022-12-07
- Completion
- 2022-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SYNB8802v1 | Other / unclassified | 1e+11 cells | Oral |
| Subject | SYNB8802v1 | Other / unclassified | 3e+11 cells | Oral |
Indications
No indication recorded.